Jazz Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $1,243,000 | $1,208,300 | $1,068,900 | $1,197,926 |
Gross Profit | 1,091,900 | 762,500 | 1,173,278 | |
EBITDA | -413,400 | 427,200 | 543,900 | 432,856 |
EBIT | 248,100 | 362,500 | 253,687 | |
Net Income | -483,400 | 192,800 | 293,100 | 203,451 |
Net Change In Cash | 1,243,000 | 1,208,300 | 1,068,900 | 1,197,926 |
Free Cash Flow | 489,900 | 397,600 | 388,500 | 296,789 |
Cash | 2,036,400 | 1,619,800 | 1,844,300 | 1,391,899 |
Basic Shares | 64,700 | 69,400 | 66,099 | 60,984 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $4,267,586 | $4,068,950 | $3,834,204 | $3,659,374 |
Gross Profit | 3,764,290 | 3,623,237 | 3,398,627 | 3,118,857 |
EBITDA | 262,757 | 1,521,711 | 1,449,422 | 1,468,615 |
EBIT | -433,540 | 861,644 | 810,726 | 839,144 |
Net Income | -356,148 | 560,120 | 414,832 | -224,060 |
Net Change In Cash | 4,267,586 | 4,068,950 | 3,834,204 | 3,659,374 |
Cost of Revenue | 296,256 | |||
Free Cash Flow | 1,146,021 | 1,347,838 | 1,068,045 | 773,783 |
Cash | 1,391,899 | 2,412,864 | 1,506,310 | 881,482 |
Basic Shares | 60,984 | 66,007 | 72,066 | 62,539 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | -$4.83 |
2026-06-30 | $4.89 |
2026-03-31 | $6.34 |
2025-12-31 | $6.64 |